Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. (Q53300225)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2003

Language	Label	Description	Also known as
English	Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.	scientific article published in June 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gordon C. Jayson

12

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

Claes Göran Tropé

14

object named as

C Tropé

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

author name string

M K B Parmar

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

J A Ledermann

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

N Colombo

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

A du Bois

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

J-F Delaloye

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

G B Kristensen

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

S Wheeler

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

A M Swart

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

W Qian

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

V Torri

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

I Floriani

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

A Lamont

13

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

ICON and AGO Collaborators

15

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

361

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

9375

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

2099-2106

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

Cancer burden in the year 2000. The global picture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913718-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(03)13718-X

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12826431

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53300225&oldid=1561396511"